Table 2.
CO-confirmed point-prevalent abstinence and initial cessation rates (%)
| Placebo | Bupropion | Lozenge | Patch | Bupropion + Lozenge |
Patch + Lozenge |
|
|---|---|---|---|---|---|---|
| Initial cessation* | 69.4 | 82.2 | 81.3 | 87.7 | 84.5 | 91.5 |
| 1 week | 23.3 | 34.5 | 29.2 | 40.5 | 37.4 | 43.4 |
| 8 weeks (end of treatment) |
30.2 | 40.2 | 40.4 | 44.7 | 50.4 | 53.6 |
| 6-months | 22.2 | 31.8 | 33.5 | 34.4 | 33.2 | 40.1 |
Initial cessation is defined as at least 1 day of abstinence during the first 7 days after the target quit day. Due to missing data n = 1424 for this analysis.